A POWERFUL RESEARCH AND
                              DEVELOPMENT ENGINE

                              Our unique ability to repeatedly and consistently translate science into medicine has led to a robust pipeline of clinical-stage medicines, all of which were discovered in our laboratories. Our investigational treatments target allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.

                              • Phase 1 trials Phase 1 trials

                                Phase 1 Trials

                                CEMIPLIMAB*

                                PD-1 Antibody Cancer

                                REGN3767

                                LAG-3 Antibody Cancer

                                REGN1979

                                CD20xCD3 Antibody Cancer

                                REGN4018*

                                MUC16xCD3 Antibody Cancer

                                REGN4659

                                CTLA4 Antibody Cancer
                                REGN5093
                                METxMET Antibody Cancer

                                REGN5458*

                                BCMAxCD3 Antibody Cancer
                                REGN5459*
                                BCMAxCD3 Antibody Cancer
                                REGN5678
                                PSMAxCD28 Antibody Cancer

                                REGN3048-3051

                                Middle East Respiratory Coronavirus Antibody MERS-CoV infection

                                REGN4461

                                LEPR Antibody Lipodystrophy and obesity
                                REGN5713-5714-5715
                                Betv1 Antibody Birch Allergy
                              • Phase 2 trials Phase 2 trials

                                Phase 2 Trials

                                AFLIBERCEPT
                                VEGF Trap High-dose for wet age-related macular degeneration (AMD)

                                CEMIPLIMAB*

                                PD-1 Antibody Basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (CSCC)
                                REGN1979
                                CD20xCD3 Antibody Relapsed/refractory follicular lymphoma

                                DUPILUMAB*

                                IL-4R Antibody Grass allergy, peanut allergy

                                SARILUMAB*

                                IL-6R Antibody Polyarticular-course juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis

                                REGN1908-1909

                                Fel d 1 Antibody Cat allergy

                                REGN3500*

                                IL-33 Antibody Asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis

                                REGN5069

                                GFRα3 Antibody Osteoarthritis knee pain

                                GARETOSMAB

                                Activin A Antibody Fibrodysplasia Ossificans Progressiva (FOP)

                                EVINACUMAB

                                ANGPTL-3 Antibody Refractory hypercholesterolemia (both HeFH and non-FH), severe hypertriglyceridemia

                                POZELIMAB

                                C5 Antibody Paroxysmal nocturnal hemoglobinuria
                              • Phase 3 trials Phase 3 trials

                                Phase 3 Trials

                                AFLIBERCEPT
                                VEGF Trap Retinopathy of Prematurity (ROP)

                                ALIROCUMAB*

                                PCSK9 Antibody Homozygous familial hypercholesterolemia (HoFH) in adults and pediatrics, heterozygous familial hypercholesterolemia in pediatrics

                                CEMIPLIMAB*

                                PD-1 Antibody Non-small cell lung cancer (NSCLC), cervical cancer, cutaneous squamous cell carcinoma (CSCC) (adjuvant)

                                REGN-EB3

                                Ebola Virus Antibody Ebola virus infection

                                DUPILUMAB*

                                IL-4R Antibody Atopic dermatitis in pediatrics, asthma in pediatric, eosinophilic esophagitis, COPD

                                SARILUMAB*

                                IL-6R Antibody Polymyalgia rheumatica, giant cell arteritis

                                EVINACUMAB

                                ANGPTL-3 Antibody Homozygous familial hypercholesterolemia (HoFH)

                                FASINUMAB?

                                NGF Antibody Chronic pain from osteoarthritis of the knee or hip
                              • IMMUNOLOGY & INFLAMMATORY DISEASES
                              • ONCOLOGY
                              • OPHTHALMOLOGY
                              • RARE DISEASES
                              • CARDIOVASCULAR/METABOLIC DISEASES
                              • INFECTIOUS DISEASES
                              • PAIN

                              Trials Footnotes

                              * in collaboration with Sanofi

                              ? in collaboration with Teva and Mitsubishi Tanabe

                              This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.

                              www,777788,coom